Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	20.79	17.19	14.62	8.04	0.95	0.22
Research & Development	69.47	64.22	38.62	14.99	7.94	3.11
Operating Expenses	90.26	81.41	53.24	23.02	8.89	3.33
Operating Income	-90.26	-81.41	-53.24	-23.02	-8.89	-3.33
Interest Expense	-	-	-	-	-0.08	-
Interest & Investment Income	5.72	5.95	1.83	0.07	-	-
Other Non Operating Income (Expenses)	-0.02	-0	-0.08	-0	-0	0
EBT Excluding Unusual Items	-84.56	-75.47	-51.49	-22.96	-8.97	-3.33
Other Unusual Items	-	-	-	-	-0.64	-
Pretax Income	-84.56	-75.47	-51.49	-22.96	-9.61	-3.33
Income Tax Expense	0.06	0.06	0.03	0	-	0
Net Income	-84.61	-75.52	-51.51	-22.96	-9.61	-3.33
Preferred Dividends & Other Adjustments	-	-	-	0.02	0.15	-
Net Income to Common	-84.61	-75.52	-51.51	-22.99	-9.76	-3.33
Shares Outstanding (Basic)	28	26	24	12	0	0
Shares Outstanding (Diluted)	28	26	24	12	0	0
Shares Change (YoY)	10.95%	7.60%	99.06%	4975.15%	0.32%	-
EPS (Basic)	-2.98	-2.87	-2.10	-1.87	-40.31	-13.79
EPS (Diluted)	-2.98	-2.87	-2.10	-1.87	-40.31	-13.79
Free Cash Flow	-75.01	-56.92	-39.32	-27.58	-7.86	-2.78
Free Cash Flow Per Share	-2.65	-2.16	-1.61	-2.24	-32.44	-11.52
EBITDA	-89.96	-81.31	-53.17	-23.01	-8.89	-
D&A For EBITDA	0.3	0.1	0.07	0.02	0	-
EBIT	-90.26	-81.41	-53.24	-23.02	-8.89	-3.33

Source: S&P Capital IQ. Standard template. Financial Sources.